wrt the MANY OTHER DRUGS that allow labelling to take care of the issue of slower start time for drug to kick in following a fatty meal: it’s the fatty meal issue not anything about bioequivalence, so far as i know.
Anyway, your message is very disturbing to a longtime investor with a lot of $$$ and high hopes into this. Hopefully we will see high revs and get bought out in the near future. please keep posting.
Weez....beautiful.!!!!.....any thoughts on why Hakimus didn't pursue the ER first instead of the IR..that would have validated the two bead..no Tmax issue....but I've been asking that question for years even though i knew the answer.